[1]
Houslay, M.D.; Schafer, P.; Zhang, K.Y. Keynote review: Phosphodiesterase-4 as a therapeutic target. Drug Discov. Today, 2005, 10(22), 1503-1519.
[2]
Lipworth, B.J. Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease. Lancet, 2005, 36(9454), 167-175.
[3]
Page, C.P.; Spina, D. Selective PDE inhibitors as novel treatments for respiratory diseases. Curr. Opin. Pharmacol., 2012, 12(3), 275-286.
[4]
Bora, R.S.; Malik, R.; Arya, R.; Gupta, D.; Singh, V.; Aggarwal, N.; Dastidar, S.; Ray, A.; Saini, K.S. A reporter gene assay for screening of PDE4 subtype selective inhibitors. Biochem. Biophys. Res. Commun., 2007, 356(1), 153-158.
[5]
Wunder, F.; Quednau, R.; Geerts, A.; Barg, M.; Tersteegen, A. Characterization of the cellular activity of PDE 4 inhibitors using two novel PDE 4 reporter cell lines. Mol. Pharm., 2013, 10(10), 3697-3705.
[6]
Bardelle, C.; Smales, C.; Ito, M.; Nomoto, K.; Wong, E.Y.; Kato, H.; Saeki, T.; Staddon, J.M. Phosphodiesterase 4 conformers: Preparation of recombinant enzymes and assay for inhibitors. Anal. Biochem., 1999, 275(2), 148-155.
[7]
Kariv, I.I.; Stevens, M.E.; Behrens, D.L.; Oldenburg, K.R. High throughput quantitation of cAMP production mediated by activation of seven transmembrane domain receptors. J. Biomol. Screen., 1999, 4(1), 27-32.
[8]
Li, Q.Y.; Xu, M.K.; Liu, G.; Christoffersen, C.T.; Wang, M.W. Discovery of novel PDE10 inhibitors by a robust homogeneous screening assay. Acta Pharmacol. Sin., 2013, 34(8), 1116-1120.
[9]
Huang, W.; Zhang, Y.; Sportsman, J.R. A fluorescence polarization assay for cyclic nucleotide phosphodiesterases. J. Biomol. Screen., 2002, 7(3), 215-222.
[10]
Staeben, M.; Kleman-Leyer, K.M.; Kopp, A.L.; Westermeyer, T.A.; Lowery, R.G. Development and validation of a transcreener assay for detection of AMP- and GMP-producing enzymes. Assay Drug Dev. Technol., 2010, 8(3), 344-355.
[11]
Chen, C.; Liu, M.; Wu, J.; Yang, X.; Hu, X.; Pu, J.; Long, G.; Xie, Y.; Jiang, H.; Yuan, Y.; Liao, F. Microplate-based method to screen inhibitors of isozymes of cyclic nucleotide phosphodiesterase fused to SUMO. J. Enzyme Inhib. Med. Chem., 2014, 29(6), 836-839.
[12]
Feng, J.; Chen, Y.; Pu, J.; Yang, X.; Zhang, C.; Zhu, S.; Zhao, Y.; Yuan, Y.; Yuan, H.; Liao, F. An improved malachite green assay of phosphate: Mechanism and application. Anal. Biochem., 2011, 409(1), 144-149.
[13]
Zhu, S.; Gan, Z.; Li, Z.; Liu, Y.; Yang, X.; Deng, P.; Xie, Y.; Yu, M.; Liao, H.; Zhao, Y.; Zhao, L.; Liao, F. The measurement of cyclic nucleotide phosphodiesterase 4 activities via the quantification of inorganic phosphate with malachite green. Anal. Chim. Acta, 2009, 636(1), 105-110.
[14]
Arya, R.; Aslam, S.; Gupta, S.; Bora, R.S.; Vijayakrishnan, L.; Gulati, P.; Naithani, S.; Mukherjee, S.; Dastidar, S.; Bhattacharya, A.; Saini, K.S. Production and characterization of pharmacologically active recombinant human phosphodiesterase 4B in Dictyostelium discoideum. Biotechnol. J., 2008, 3(7), 938-947.
[15]
Saldou, N.; Obernolte, R.; Huber, A.; Baecker, P.A.; Wilhelm, R.; Alvarez, R.; Li, B.; Xia, L.; Callan, O.; Su, C.; Jarnagin, K.; Shelton, E.R. Comparison of recombinant human PDE4 isoforms: interaction with substrate and inhibitors. Cell. Signal., 1998, 10(6), 427-440.
[16]
Rocque, W.J.; Tian, G.; Wiseman, J.S.; Holmes, W.D.; Zajac-Thompson, I.; Willard, D.H.; Patel, I.R.; Wisely, G.B.; Clay, W.C.; Kadwell, S.H.; Hoffman, C.R.; Luther, M.A. Human recombinant phosphodiesterase 4B2B binds (R)-rolipram at a single site with two affinities. Biochemistry, 1997, 36(46), 14250-14261.
[17]
Rocque, W.J.; Holmes, W.D.; Patel, I.R.; Dougherty, R.W.; Ittoop, O.; Overton, L.; Hoffman, C.R.; Wisely, G.B.; Willard, D.H.; Luther, M.A. Detailed characterization of a purified type 4 phosphodiesterase.; HSPDE4B2B: Differentiation of high- and low-affinity (R)-rolipram binding. Protein Expr. Purif., 1997, 9(2), 191-202.
[18]
Wang, P.; Myers, J.G.; Wu, P.; Cheewatrakoolpong, B.; Egan, R.W.; Billah, M.M. Expression, purification, and characterization of human cAMP-specific phosphodiesterase (PDE4) subtypes A, B, C and D. Biochem. Biophys. Res. Commun., 1997, 234(2), 320-324.
[19]
Salanova, M.; Jin, S.C.; Conti, M. Heterologous expression and purification of recombinant rolipram-sensitive cyclic AMP-specific phosphodiesterases. Methods, 1998, 14(1), 55-64.
[20]
Gurney, M.E.; Burgin, A.B.; Magnusson, O.T.; Stewart, L.J. Small molecule allosteric modulators of phosphodiesterase 4. Handb. Exp. Pharmacol., 2011, (204), 167-192.
[21]
Xie, M.; Blackman, B.; Scheitrum, C.; Mika, D.; Blanchard, E.; Lei, T.; Conti, M.; Richter, W. The upstream conserved regions (UCRs) mediate homo- and hetero-oligomerization of type 4 cyclic nucleotide phosphodiesterases (PDE4s). Biochem. J., 2014, 459(3), 539-550.
[22]
Souness, J.E.; Rao, S. Proposal for pharmacologically distinct conformers of PDE4 cyclic AMP phosphodiesterases. Cell. Signal., 1997, 9(3-4), 227-236.
[23]
Zhu, S.; Yang, G.; Yang, X.; Zhao, Y.; Li, X.; Deng, P.; Xie, Y.; Gan, Z.; Liu, Y.; Li, Z.; Liao, J.; Yu, M.; Liao, F. Soluble expression in Escherichia coli of active human cyclic nucleotide phosphodiesterase isoform 4B2 in fusion with maltose-binding protein. Biosci. Biotechnol. Biochem., 2009, 73(4), 968-970.
[24]
Zhang, Y.; Yang, X.; Hu, X.; Liu, M.; Chen, C.; Xie, Y.; Pu, J.; Wu, J.; Long, G.; Liao, F. Resonant-Mie-scattering of aggregates of phosphomolybdate and papaverine for measuring activities and screening inhibitors of cyclic nucleotide phosphodiesterase isozymes. Anal. Chim. Acta, 2013, 804, 215-220.
[25]
Ashton, M.J.; Cook, D.C.; Fenton, G.; Karlsson, J.A.; Palfreyman, M.N.; Raeburn, D.; Ratcliffe, A.J.; Souness, J.E.; Thurairatnam, S.; Vicker, N. Selective type IV phosphodiesterase inhibitors as antiasthmatic agents.The syntheses and biological activities of 3-(cyclopentyloxy)-4-methoxybenzamides and analogues. J. Med. Chem., 1994, 37(11), 1696-1703.
[26]
Day, J.P.; Lindsay, B.; Riddell, T.; Jiang, Z.; Allcock, R.W.; Abraham, A.; Sookup, S.; Christian, F.; Bogum, J. Marti,n E.K.; Rae, R.L.; Anthony, D.; Rosair, G.M.; Houslay, D.M.; Huston, E.; Baillie, G.S.; Klussmann, E.; Houslay, M.D.; Adams, D.R. Elucidation of a structural basis for the inhibitor-driven, p62 (SQSTM1)-dependent intracellular redistribution of cAMP phosphodiesterase-4A4 (PDE4A4). J. Med. Chem., 2011, 54(9), 3331-3347.
[27]
Yuan, M.; Yang, X.; Li, Y.; Liu, H.; Pu, J.; Zhan, C.G.; Liao, F. Facile alkaline lysis of Echerichia coli cells in high-throughput mode for screening enzyme mutants: Arylsulfatase as an example. Appl. Biochem. Biotechnol., 2016, 179(4), 545-557.
[28]
Li, Y.; Yang, X.; Wang, D.; Hu, X.; Yuan, M.; Pu, J.; Zhan, C-G.; Yang, Z.; Liao, F. Striking effects of storage buffers on apparent half-lives of the activity of pseudomonas aeruginosa arylsulfatase. Protein J., 2016, 35(4), 283-290.
[29]
Bradford, M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem., 1976, 72, 248-254.
[30]
Qi, M.; Zhang, G.P. An investigation of model selection criteria for neural network time series forecasting. Eur. J. Oper. Res., 2001, 132(1), 666-680.
[31]
Li, Y.; Long, G.; Yang, X.; Hu, X.; Feng, Y.; Tan, D.; Xie, Y.; Pu, J.; Liao, F. Approximated maximum adsorption of His-tagged enzyme/mutants on Ni2+-NTA for comparison of specific activities. Int. J. Biol. Macromol., 2015, 74, 211-217.
[32]
You, C.; Okano, H.; Hui, S.; Zhang, Z.; Kim, M.; Gunderson, C.W.; Wang, Y.P.; Lenz, P. Ya,n D.; Hwa, T. Coordination of bacterial proteome with metabolism by cyclic AMP signalling. Nature, 2013, 500(7462), 301-306.
[33]
Malo, N.; Hanley, J.A.; Cerquozzi, S.; Pelletier, J.; Nadon, R. Statistical practice in high-throughput screening data analysis. Nat. Biotechnol., 2006, 24(2), 167-175.
